Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965782 | 0.94 | SIGMAR1 (0.53) | SIGMAR1CYP1A2BCHEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4348821 | 0.92 | SIGMAR1 (0.52) | SIGMAR1CYP1A2BCHEMEN1KMT2A | |
| SCHEMBL14176596 | 0.85 | MEN1 (0.47) | SIGMAR1CYP1A2BCHEMEN1KMT2A | |
| SCHEMBL8394039 | 0.85 | SIGMAR1 (0.42) | SIGMAR1CYP1A2BCHEMEN1KMT2A | |
| SCHEMBL16311942 | 0.82 | SIGMAR1 (0.43) | SIGMAR1MEN1KMT2A | |
| SCHEMBL20666382 | 0.82 | MEN1 (0.45) | SIGMAR1CYP1A2BCHEMEN1KMT2A | |
| SCHEMBL28668294 | 0.81 | SIGMAR1 (0.50) | SIGMAR1CYP1A2BCHEEPHX1 | |
| SCHEMBL26431397 | 0.78 | SIGMAR1 (0.96) | SIGMAR1CYP1A2TNKS2EPHX1 | |
| SCHEMBL6975263 | 0.78 | SIGMAR1 (0.96) | SIGMAR1CYP1A2TNKS2EPHX1 | |
| SCHEMBL25123272 | 0.78 | SIGMAR1 (0.40) | SIGMAR1CYP1A2BCHEEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371293-A1 | Amine Cationic Lipids and Uses Thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110281908-A1 | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371293-A1 | Amine Cationic Lipids and Uses Thereof | SGMS2, SLC43A1, SGMS1 | SIGMAR1 666/4885CYP1A2 4850/4885BCHE 2943/4885 |
| US-20110281908-A1 | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | HSP90AB1, HSP90AB2P, HSP90AA1 | SIGMAR1 3501/4885CYP1A2 2780/4885BCHE 2653/4885 |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | HSP90AB1, HSP90AA1, HSP90AB2P | SIGMAR1 3928/4885CYP1A2 3967/4885BCHE 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.